Pilot trial of FANG immunotherapy in ewing's sarcoma

Molecular Therapy

Volumn 23, Issue 6, 2015, Pages 1103-1109

  Ghisoli, Maurizio ^a,b,d   Barve, Minal ^a,b   Schneider, Reva ^a,b,c   Mennel, Robert ^b,e   Lenarsky, Carl ^b,d   Wallraven, Gladice ^c   Pappen, Beena O ^c   Lanoue, John ^f   Kumar, Padmasini ^c   Nemunaitis, Derek ^a   Roth, Alyssa ^a   Nemunaitis, James ^a   Whiting, Sam ^c   Senzer, Neil ^a,c   Fletcher, Frederick A ^c   Nemunaitis, John ^a,b,c,d  

^a Mary Crowley Cancer Research Centers   (United States)

^b TEXAS ONCOLOGY   (United States)

^c GRADALIS INC   (United States)

^d MEDICAL CITY DALLAS HOSPITAL   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f Medical City Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; GAMMA INTERFERON;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MALE; MIDDLE AGED; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; YOUNG ADULT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; METABOLISM; MONONUCLEAR CELL; NEOPLASM METASTASIS; PROCEDURES; SARCOMA, EWING;

ADOLESCENT; ADULT; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; SARCOMA, EWING; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930177428     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.43     Document Type: Article

References (64)

1. Mariño-Enríquez, A and Fletcher, CD (2014). Round cell sarcomas - biologically important refinements in subclassification. Int J Biochem Cell Biol 53: 493-504
2. Arvand, A and Denny, CT (2001). Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20: 5747-5754
3. Cotterill, SJ, Ahrens, S, Paulussen, M, Jürgens, HF, Voúte, PA, Gadner, H et al. (2000). Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18: 3108-3114
4. Stahl, M, Ranft, A, Paulussen, M, Bölling, T, Vieth, V, Bielack, S et al. (2011). Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57: 549-553
5. Meyers, PA, Krailo, MD, Ladanyi, M, Chan, KW, Sailer, SL, Dickman, PS et al. (2001). High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19: 2812-2820
6. Grier, HE, Krailo, MD, Tarbell, NJ, Link, MP, Fryer, CJ, Pritchard, DJ et al. (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348: 694-701
7. Rodriguez-Galindo, C, Billups, CA, Kun, LE, Rao, BN, Pratt, CB, Merchant, TE et al. (2002). Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 94: 561-569
8. Bacci, G, Ferrari, S, Mercuri, M, Longhi, A, Giacomini, S, Forni, C et al. (2003). Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. J Pediatr Hematol Oncol 25: 118-124
9. Shankar, AG, Ashley, S, Craft, AW and Pinkerton, CR (2003). Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 40: 141-147
10. Barker, LM, Pendergrass, TW, Sanders, JE and Hawkins, DS (2005). Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23: 4354-4362
11. McTiernan, AM, Cassoni, AM, Driver, D, Michelagnoli, MP, Kilby, AM and Whelan, JS (2006). Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution. Sarcoma 2006: 83548
12. Leavey, PJ and Collier, AB (2008). Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 8: 617-624
13. Rasper, M, Jabar, S, Ranft, A, Jürgens, H, Amler, S and Dirksen, U (2014). The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 61: 1382-1386
14. Esiashvili, N, Goodman, M and Marcus, RB Jr (2008). Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425-430
15. Berghuis, D, Santos, SJ, Baelde, HJ, Taminiau, AH, Egeler, RM, Schilham, MW et al. (2011). Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 223: 347-357
16. Evans, CH, Liu, F, Porter, RM, O'Sullivan, RP, Merghoub, T, Lunsford, EP et al. (2012). EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clin Cancer Res 18: 5341-5351
17. Berghuis, D, De Hooge, AS, Santos, SJ, Horst, D, Wiertz, EJ, van Eggermond, MC et al. (2009). Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 218: 222-231
18. Nemunaitis, J (2011). Multifunctional vaccines in cancer: the 'triad' approach. Expert Rev Vaccines 10: 713-715
19. Senzer, N, Barve, M, Kuhn, J, Melnyk, A, Beitsch, P, Lazar, M et al. (2012). Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 20: 679-686
20. Senzer, N, Barve, M, Nemunaitis, J, Kuhn, J, Melnyk, A, Beitsch, P et al. (2013). Long term follow up: phase I trial of "bi-shRNA furin/GMCSF DNA/ autologous tumor cell" immunotherapy (FANG') in advanced cancer. J Vaccines Vaccin 4: 209
21. Maples, PB, Kumar, P, Yu, Y, Wang, Z, Jay, C, Pappen, BO et al. (2010). FANG vaccine: autologous tumor vaccine genetically modified to express GM-CSF and block production of furin. BioProcess J 8: 4-14
22. Olivares, J, Kumar, P, Yu, Y, Maples, PB, Senzer, N, Bedell, C et al. (2011). Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 17: 183-192
23. Thiel, U, Pirson, S, Müller-Spahn, C, Conrad, H, Busch, DH, Bernhard, H et al. (2011). Specific recognition and inhibition of Ewing tumour growth by antigen-specific allorestricted cytotoxic T cells. Br J Cancer 104: 948-956
24. Mahlendorf, De and Staege, MS (2013). Characterization of Ewing sarcoma associated cancer/testis antigens. Cancer Biol Ther 14: 254-261
25. Yabe, H, Tsukahara, T, Kawaguchi, S, Wada, T, Torigoe, T, Sato, N et al. (2011). Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. J Surg Oncol 103: 380-385
26. Peters, HL, Yan, Y, Nordgren, TM, Cutucache, CE, Joshi, SS and Solheim, JC (2013). Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biol Ther 14: 752-760
27. Kailayangiri, S, Altvater, B, Meltzer, J, Pscherer, S, Luecke, A, Dierkes, C et al. (2012). The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106: 1123-1133
28. Liebsch, L, Kailayangiri, S, Beck, L, Altvater, B, Koch, R, Dierkes, C et al. (2013). Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer 109: 658-666
29. Cho, D, Shook, DR, Shimasaki, N, Chang, YH, Fujisaki, H and Campana, D (2010). Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901-3909
30. Mackall, CL, Rhee, EH, Read, EJ, Khuu, HM, Leitman, SF, Bernstein, D et al. (2008). A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14: 4850-4858
31. Sporn, MB, Roberts, AB, Wakefield, LM and Assoian, RK (1986). Transforming growth factor-beta: biological function and chemical structure. Science 233: 532-534
32. Massagué, J (1987). The TGF-beta family of growth and differentiation factors. Cell 49: 437-438
33. Border, WA and Ruoslahti, E (1992). Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 90: 1-7
34. Jachimczak, P, Bogdahn, U, Schneider, J, Behl, C, Meixensberger, J, Apfel, R et al. (1993). The effect of transforming growth factor-beta 2-specific phosphorothioateanti- sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78: 944-951
35. Merzak, A, McCrea, S, Koocheckpour, S and Pilkington, GJ (1994). Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 70: 199-203
36. Jennings, MT, Kaariainen, IT, Gold, L, Maciunas, RJ and Commers, PA (1994). TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis. Hum Pathol 25: 464-475
37. Jennings, MT and Pietenpol, JA (1998). The role of transforming growth factor beta in glioma progression. J Neurooncol 36: 123-140
38. Ashley, DM, Kong, FM, Bigner, DD and Hale, LP (1998). Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 58: 302-309
39. Ashley, DM, Sampson, JH, Archer, GE, Hale, LP and Bigner, DD (1998). Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. J Neuroimmunol 86: 46-52
40. Bierie, B and Moses, HL (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520
41. Pardali, K and Moustakas, A (2007). Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62
42. Hanahan, D and Weinberg, RA (2000). The hallmarks of cancer. Cell 100: 57-70
43. Levy, L and Hill, CS (2006). Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58
44. Sorbye, SW, Kilvaer, TK, Valkov, A, Donnem, T, Smeland, E, Al-Shibli, K et al. (2012). Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 12: 7
45. Bodmer, S, Strommer, K, Frei, K, Siepl, C, De Tribolet, N, Heid, I et al. (1989). Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143: 3222-3229
46. Chen, TC, Hinton, DR, Yong, VW and Hofman, FM (1997). TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. J Neuroimmunol 73: 155-161
47. Li, MO, Wan, YY, Sanjabi, S, Robertson, AK and Flavell, RA (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146
48. Fakhrai, H, Dorigo, O, Shawler, DL, Lin, H, Mercola, D, Black, KL et al. (1996). Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914
49. Scarlett, UK, Rutkowski, MR, Rauwerdink, AM, Fields, J, Escovar-Fadul, X, Baird, J et al. (2012). Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209: 495-506
50. Thomas, DA and Massagué, J (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380
51. Rook, AH, Kehrl, JH, Wakefield, LM, Roberts, AB, Sporn, MB, Burlington, DB et al. (1986). Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-3920
52. Kasid, A, Bell, GI and Director, EP (1988). Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141: 690-698
53. Tsunawaki, S, Sporn, M, Ding, A and Nathan, C (1988). Deactivation of macrophages by transforming growth factor-beta. Nature 334: 260-262
54. Hirte, H and Clark, DA (1991). Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 32: 296-302
55. Ruffini, PA, Rivoltini, L, Silvani, A, Boiardi, A and Parmiani, G (1993). Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36: 409-416
56. Naganuma, H, Sasaki, A, Satoh, E, Nagasaka, M, Nakano, S, Isoe, S et al. (1996). Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokineactivated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) 36: 789-795
57. Yamaguchi, Y, Tsumura, H, Miwa, M and Inaba, K (1997). Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15: 144-153
58. Geissmann, F, Revy, P, Regnault, A, Lepelletier, Y, Dy, M, Brousse, N et al. (1999). TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 162: 4567-4575
59. Steinman, RM, Hawiger, D, Liu, K, Bonifaz, L, Bonnyay, D, Mahnke, K et al. (2003). Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann NY Acad Sci 987: 15-25
60. Ashcroft, GS (1999). Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect 1: 1275-1282
61. Takeuchi, M, Alard, P and Streilein, JW (1998). TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol 160: 1589-1597
62. Du, C and Sriram, S (1998). Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-beta in ANA-1 cells. J Leukoc Biol 64: 92-97
63. Nemunaitis, JJ, Senzer, NN, Barve, MA, Oh, J, Kumar, P, Rao, D et al. (2014). Survival effect of bi-shRNAfurin/GMCSF DNA based immunotherapy (FANG') in 123 advanced cancer patients to alpha-interferon-ELISPOT response. J Clin Oncol 32: 5s (suppl; abstr 3077)
64. Oh, J, Barve, M, Bedell, C, Kuhn, J, Fine, B, Heffernan, TP et al. (2014). Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG') for High Risk Stage III/IV Ovarian Cancer: Preliminary Results (Poster #624). In ASGCT 17th Annual Meeting, Washington, DC.